SR

Scholar Rock Holding CorpNASDAQ SRRK Stock Report

Last reporting period 30 Sep, 2023

Updated 12 Nov, 2024

Last price

Market cap $B

0.691

Micro

Exchange

XNAS - Nasdaq

SRRK Stock Analysis

SR

Uncovered

Scholar Rock Holding Corp is uncovered by Eyestock quantitative analysis.

Market cap $B

0.691

Dividend yield

Shares outstanding

51.985 B

Scholar Rock Holding Corp. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 114 full-time employees. The company went IPO on 2018-05-24. The Company’s product candidate includes apitegromab, an inhibitor of the activation of latent myostatin for the treatment of spinal muscular atrophy (SMA) and is in the treatment of other myostatin-related disorders. Its product candidate also includes SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 (TGFβ1) for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies. Its selective inhibitors of the activation of transforming growth factor-beta (TGFβ) for the treatment of fibrotic diseases. The company is advancing multiple antibody profiles toward product candidate selection, including antibodies that selectively inhibit the activation of latent TGFβ1 in the context of fibrotic extracellular matrix and that avoid perturbing TGFβ1 presented by cells of the immune system.

View Section: Eyestock Rating